Foghorn Therapeutics Inc (FHTX) Stock Analysis

Foghorn Therapeutics Inc (FHTX) is a publicly traded company in the HEALTHCARE sector. It trades at $3.63, carries a market capitalization of $251.30M. This page summarizes the public market data, fundamentals, and frequently asked questions for FHTX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Foghorn Therapeutics Inc currently has a Neutral sentiment score of 0.05.

About Foghorn Therapeutics Inc

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on pioneering therapies that target genetic dependencies within the chromatin regulatory system. Utilizing its proprietary Gene Traffic Control platform, the company is advancing a promising pipeline of therapeutic candidates aimed at treating various cancers and genetic disorders, thereby establishing itself as a key player in the precision medicine landscape. With a com...

GNG Research Analysis

GNG Research scores Foghorn Therapeutics Inc (FHTX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for FHTX.

Frequently Asked Questions

Does FHTX pay dividends?

Foghorn Therapeutics Inc (FHTX) does not currently pay a regular dividend.

What is FHTX's market cap?

Foghorn Therapeutics Inc (FHTX) has a market capitalization of $251.30M with a current stock price of $3.63.